OPDIVO intravenous infusion 240mg (オプジーボ点滴静注240mg)

Kraj: Japonia

Język: angielski

Źródło: すりの適正使用協議会 RAD-AR Council, Japan

Składnik aktywny:

Nivolumab (genetical recombination)

Dostępny od:

Ono Pharmaceutical Co., Ltd.

INN (International Nazwa):

Nivolumab (genetical recombination)

Forma farmaceutyczna:

injection

Ulotka dla pacjenta

Drug Information Sheet("Kusuri-no-Shiori")
Injection
Revised: 02/2024
The information on this sheet is based on approvals granted by the
Japanese regulatory authority. Approval
details may vary by country. Medicines have adverse reactions (risks)
as well as efficacies (benefits). It is
important to minimize adverse reactions and maximize efficacy. To
obtain a better therapeutic response,
patients should understand their medication and cooperate with the
treatment.
BRAND NAME:
OPDIVO INTRAVENOUS INFUSION 240MG
ACTIVE INGREDIENT:
Nivolumab (genetical recombination)
DOSAGE FORM:
injection
IMPRINT OR PRINT ON WRAPPING:
EFFECTS OF THIS MEDICINE
This medicine inhibits binding of cancer cell to T-cell (immune cell)
via PD-1 receptor and
promotes T-cell activation. It consequently enhances immune response
to cancer and shows
antitumor effect. It is usually used to treat malignant melanoma,
unresectable
advanced/recurrent non-small cell lung cancer, neoadjuvant treatment
of non-small cell lung
cancer, radically unresectable or metastatic renal cell carcinoma,
recurrent or refractory
classical Hodgkin's lymphoma, recurrent or distant metastatic head and
neck cancer,
unresectable advanced/recurrent gastric cancer, unresectable
advanced/recurrent malignant
pleural mesothelioma, malignant mesothelioma (excluding malignant
pleural mesothelioma),
microsatellite instability high (MSI-High) unresectable
advanced/recurrent colorectal cancer
progressing after cancer chemotherapy, radically unresectable
advanced/recurrent
esophageal cancer, adjuvant treatment of esophageal cancer, cancer of
unknown primary,
adjuvant treatment of urothelial cancer and radically unresectable
advanced/recurrent
malignant epithelial tumors.
THE FOLLOWING PATIENTS MAY NEED TO BE CAREFUL WHEN USING THIS
MEDICINE.BE SURE TO TELL YOUR DOCTOR
AND PHARMACIST.
・If you have previously experienced any allergic reactions (itch,
rash, etc.) to any medicines
or foods.
If you have autoimmune disorder or its history, or interstitial
pulmonary disease or its history